PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Dow will close chemicals plants on top of job cuts

DOW has announced it will close manufacturing sites in Europe and North America as it seeks to cut costs in response to Covid-19.

The chemicals major said in July that it would make savings of more than US$300m by the end of 2021. This included making 6% of staff – around 2,200 people – redundant. On 30 September, Dow updated its plans, noting it would close a number of manufacturing plants, though has not disclosed their exact locations.

It said the closures would include some amines and solvents facilities in the US and Europe; some small-scale downstream polyurethanes plants; small coating reactors; and siloxane and silicon metal plants in Europe, Canada and the US.

“Given the expected gradual and uneven global economic recovery from Covid-19, we announced in July that we are taking necessary actions to continue to optimise our asset footprint, reduce structural costs and enhance the competitiveness of our business over the long-term,” said Dow CEO Jim Fitterling.

Separately, the company has set targets to reduce operating expenses by US$500m by the end of 2020 and has reduced year-on-year capital expenditure to US$1.35bn from US$2bn last year. It has also sold its rail infrastructure assets at six North American sites for US$310m and announced plans to sell some of its marine and terminal operations to Vopak for US$620m by the end of the year.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026